source
- Biogen’s early Phase 2 data supports tau-targeting Alzheimer’s approachBiogen has released early Phase 2 results for its experimental Alzheimer’s therapy diranersen, indicating that reducing tau protein levels may lead to cognitive benefits. The findings add to a lon…
- Red Bull-funded studies downplay risks of mixing energy drinks with alcohol, shaping policy despite independent warningsAn investigative report found that research funded by the energy‑drink maker contradicted the bulk of independent studies on the dangers of combining alcohol with caffeinated beverages. The funded…